These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33639674)

  • 1. Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective.
    Shah SZ; Raza N; Nasir MI; Zaidi SMH
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):559-564. PubMed ID: 33639674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
    Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
    Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency Of Raised Serum Lactate Dehydrogenase In Patients With Jak2 Positive Polycythaemia Vera.
    Shah SZ; Raza N; Irfan M
    J Ayub Med Coll Abbottabad; 2021; 33(3):447-450. PubMed ID: 34487654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.
    Sultan S; Irfan SM; Khan SR
    Asian Pac J Cancer Prev; 2016; 17(3):1053-5. PubMed ID: 27039724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
    Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
    Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
    Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
    Shen YF; Xia J; Lu MZ; Jiang YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Ruzzon E; Tezza F; Scapin M; Duner E; Scandellari R; Fabris F
    Aging Clin Exp Res; 2011 Feb; 23(1):17-21. PubMed ID: 21499015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing essential thrombocythemia
    Silver RT; Krichevsky S
    Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
    Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.